Background:
Prior studies demonstrate a higher prevalence of pulmonary hypertension (PH) and more severe hemodynamics in patients with higher body mass index (BMI). However, this association was only described in post-capillary PH. To better understand the relationship between pre-capillary PH and BMI, we compared various PH parameters stratified by BMI class.
Methods:
Data from right heart catheterization (RHC), 6-minute walk (6MW), and functional class (FC) were collected from the University of Michigan Pulmonary Hypertension Patient Registry from 2016-2020 at baseline and 3-month follow-up. Group 1 pulmonary arterial hypertension (PAH) patients were grouped into 4 BMI weight classes: under/normal weight (BMI < 25), overweight (25 < BMI < 30), obesity class 1 (30 < BMI < 35), obesity class 2/3 (BMI > 35).
Results:
Among 175 PAH patients, obese patients exhibited higher right atrial and pulmonary capillary wedge pressures. There were no major differences in mean pulmonary artery (PA) pressures, pulmonary vascular resistance (PVR), cardiac index Fick, 6MW distance walked, or peak Borg Dyspnea score among BMI groups. Despite having similar mean PA pressure and PVR (major determinants of functional capacity in PAH), patients in higher weight classes had higher dyspnea symptom burden by WHO FC. Specifically, a greater prevalence of normal/overweight patients were in FC 1 while more obese patients were in FC 3.
Conclusions:
Overall, in patients with PAH, higher BMI classes presented with worse FC for dyspnea, higher RA and PCW pressures, with similar PA pressures and 6MW results. Our data suggests that BMI may be an important factor that influences PAH symptoms. The impact of BMI in PAH outcomes is yet to be determined. It is possible that patients with higher BMI may exhibit more frequent comorbid conditions contributing to multifactorial symptoms of dyspnea; further study is warranted.
Background:
Approximately 1/3 of acute pulmonary embolism (PE) patients develop chronic thromboembolic disease (CTED), a condition in which a patient’s PE does not resolve after standard anticoagulation therapy. Chronic thromboembolic pulmonary hypertension (CTEPH) can occur in about 3-4% of acute PE patients. Though CTED and CTEPH share an underlying cause, few studies have compared symptom severity, patient history, and other clinical indicators for the two diseases. Moreover, CTED is sometimes considered to be an asymptomatic condition. The symptomatology in CTEPH is thought to be primarily determined by pulmonary hypertension, a characteristic that CTED patients do not share.
Methods:
Data were collected at baseline diagnosis from 24 CTED and 65 CTEPH patients in the University of Michigan Pulmonary Hypertension Registry between 2016-2020. Demographic, 6-minute walk (6MW), echocardiography, past medical history, and brain natriuretic peptide (BNP) data were compared between groups.
Results:
CTED patients were: 1) less symptomatic (better WHO functional class [FC], better predicted 6MW), 2) had more preserved oxygenation during 6MW, 3) had less RV dilation/dysfunction and RA dilation on echo, and 4) lower BNP, than CTEPH patients. Despite this, 54% of CTED patients demonstrated significantly impaired FC (III/IV) without evidence of significant RV dysfunction, exercise hypoxia or volume overload.
Conclusion:
More than half of CTED patients in our study had significantly impaired FC. Further investigation into CTED symptomatology is warranted. CTEPH patients are more symptomatic and present with worse clinical metrics than CTED patients, which may be attributed to more advanced RV dysfunction and higher BNP level. These results may help distinguish CTED v. CTEPH diagnoses earlier, leading to earlier targeted treatment and better outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.